1
|
Qin H, Liu J, Yu M, Wang H, Thomas AM, Li S, Yan Q, Wang L. FUT7 promotes the malignant transformation of follicular thyroid carcinoma through α1,3-fucosylation of EGF receptor. Exp Cell Res 2020; 393:112095. [PMID: 32442537 DOI: 10.1016/j.yexcr.2020.112095] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 03/18/2020] [Accepted: 05/18/2020] [Indexed: 02/07/2023]
Abstract
Aberrant protein glycosylation is involved in many diseases including cancer. This study investigated the role of fucosyltransferase VII (FUT7) in the progression of follicular thyroid carcinoma (FTC). FUT7 expression was found to be upregulated in FTC compared to paracancerous thyroid tissue, and in FTC with T2 stage of TMN classification compared to FTC with T1 stage. FUT7 overexpression promoted cell proliferation, epithelial-mesenchymal transition (EMT), and the migration and invasion of primary FTC cell line FTC-133. Consistently, FUT7 knock-down inhibited cell proliferation, EMT, as well as the migration and invasion of the metastatic FTC cell line FTC-238. Mechanistic investigation revealed that FUT7 catalyzed the α1,3-fucosylation of epidermal growth factor receptor (EGFR) in FTC cells. The extent of glycan α1,3-fucosylation on EGFR was positively correlated with the activation of EGFR in the presence/absence of epidermal growth factor (EGF) treatment. Furthermore, FUT7 was shown to enhance EGF-induced progression of FTC cells through mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathways. These findings provide a new perspective on FUT7 that may be a novel diagnostic and therapeutic target of FTC.
Collapse
Affiliation(s)
- Huamin Qin
- Department of Pathology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China
| | - Jianwei Liu
- Department of Biochemistry and Molecular Biology, Dalian Medical University, Liaoning Provincial Core Lab of Glycobiology and Glycoengineering, Dalian, China
| | - Ming Yu
- Department of Biochemistry and Molecular Biology, Dalian Medical University, Liaoning Provincial Core Lab of Glycobiology and Glycoengineering, Dalian, China
| | - Hao Wang
- Department of Biochemistry and Molecular Biology, Dalian Medical University, Liaoning Provincial Core Lab of Glycobiology and Glycoengineering, Dalian, China
| | - Aline M Thomas
- The Russell H. Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Shen Li
- Department of Neurology, Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, China
| | - Qiu Yan
- Department of Biochemistry and Molecular Biology, Dalian Medical University, Liaoning Provincial Core Lab of Glycobiology and Glycoengineering, Dalian, China.
| | - Lifen Wang
- Department of Pathology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
| |
Collapse
|
2
|
Minskaia E, Saraiva BC, Soares MMV, Azevedo RI, Ribeiro RM, Kumar SD, Vieira AIS, Lacerda JF. Molecular Markers Distinguishing T Cell Subtypes With TSDR Strand-Bias Methylation. Front Immunol 2018; 9:2540. [PMID: 30455694 PMCID: PMC6230625 DOI: 10.3389/fimmu.2018.02540] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Accepted: 10/15/2018] [Indexed: 12/28/2022] Open
Abstract
Human regulatory CD4+CD25+FOXP3+ T cells (Treg) play important roles in the maintenance of self-tolerance and immune homeostasis in various disease settings and are also involved in the suppression of effective immune responses. These cells are heterogeneous in phenotype and function, and the ability to reliably distinguish between various FOXP3-expressing subpopulations can affect the development of successful therapies. This study demonstrates that hypomethylated CpG sites, present in four regions of the FOXP3 locus, CAMTA1 and FUT7 gene regions, can be used to distinguish several subsets of Treg from conventional CD4+ T lymphocytes (Tcon) in donors of both genders. We describe a previously unreported strand-bias hemimethylation pattern in FOXP3 promoter and TSDR in donors of both genders, with the coding strand being demethylated within promoter and methylated within TSDR in all CD4+ lymphocyte subtypes, whereas the template strand follows the previously described pattern of methylation with both regions being more demethylated in Treg subtypes and mostly methylated in Tcon. This strand-specific approach within the TSDR may prove to be instrumental in correctly defining Treg subsets in health and in disease.
Collapse
Affiliation(s)
- Ekaterina Minskaia
- Faculdade de Medicina da Universidade de Lisboa, Instituto de Medicina Molecular-João Lobo Antunes, Lisbon, Portugal
| | - Barbara C Saraiva
- Faculdade de Medicina da Universidade de Lisboa, Instituto de Medicina Molecular-João Lobo Antunes, Lisbon, Portugal
| | - Maria M V Soares
- Faculdade de Medicina da Universidade de Lisboa, Instituto de Medicina Molecular-João Lobo Antunes, Lisbon, Portugal
| | - Rita I Azevedo
- Faculdade de Medicina da Universidade de Lisboa, Instituto de Medicina Molecular-João Lobo Antunes, Lisbon, Portugal
| | - Ruy M Ribeiro
- Departmento de Biomatemática, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
| | - Saumya D Kumar
- Faculdade de Medicina da Universidade de Lisboa, Instituto de Medicina Molecular-João Lobo Antunes, Lisbon, Portugal
| | - Ana I S Vieira
- Faculdade de Medicina da Universidade de Lisboa, Instituto de Medicina Molecular-João Lobo Antunes, Lisbon, Portugal
| | - João F Lacerda
- Faculdade de Medicina da Universidade de Lisboa, Instituto de Medicina Molecular-João Lobo Antunes, Lisbon, Portugal
| |
Collapse
|
3
|
Pink M, Ratsch BA, Mardahl M, Durek P, Polansky JK, Karl M, Baumgrass R, Wallner S, Cadenas C, Gianmoena K, Floess S, Chen W, Nordstroem K, Tierling S, Olek S, Walter J, Hamann A, Syrbe U. Imprinting of Skin/Inflammation Homing in CD4+ T Cells Is Controlled by DNA Methylation within the Fucosyltransferase 7 Gene. THE JOURNAL OF IMMUNOLOGY 2016; 197:3406-3414. [PMID: 27591321 DOI: 10.4049/jimmunol.1502434] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Accepted: 08/08/2016] [Indexed: 11/19/2022]
Abstract
E- and P-selectin ligands (E- and P-ligs) guide effector memory T cells into skin and inflamed regions, mediate the inflammatory recruitment of leukocytes, and contribute to the localization of hematopoietic precursor cells. A better understanding of their molecular regulation is therefore of significant interest with regard to therapeutic approaches targeting these pathways. In this study, we examined the transcriptional regulation of fucosyltransferase 7 (FUT7), an enzyme crucial for generation of the glycosylated E- and P-ligs. We found that high expression of the coding gene fut7 in murine CD4+ T cells correlates with DNA demethylation within a minimal promoter in skin/inflammation-seeking effector memory T cells. Retinoic acid, a known inducer of the gut-homing phenotype, abrogated the activation-induced demethylation of this region, which contains a cAMP responsive element. Methylation of the promoter or mutation of the cAMP responsive element abolished promoter activity and the binding of CREB, confirming the importance of this region and of its demethylation for fut7 transcription in T cells. Furthermore, studies on human CD4+ effector memory T cells confirmed demethylation within FUT7 corresponding to high FUT7 expression. Monocytes showed an even more extensive demethylation of the FUT7 gene whereas hepatocytes, which lack selectin ligand expression, exhibited extensive methylation. In conclusion, we show that DNA demethylation within the fut7 gene controls selectin ligand expression in mice and humans, including the inducible topographic commitment of T cells for skin and inflamed sites.
Collapse
Affiliation(s)
- Matthias Pink
- Experimental Rheumatology, German Rheumatism Research Center, 10117 Berlin, Germany
| | - Boris A Ratsch
- Experimental Rheumatology, German Rheumatism Research Center, 10117 Berlin, Germany
| | - Maibritt Mardahl
- Experimental Rheumatology, German Rheumatism Research Center, 10117 Berlin, Germany
| | - Pawel Durek
- Experimental Rheumatology, German Rheumatism Research Center, 10117 Berlin, Germany
| | - Julia K Polansky
- Experimental Rheumatology, German Rheumatism Research Center, 10117 Berlin, Germany
| | - Martin Karl
- Signal Transduction, German Rheumatism Research Center, 10117 Berlin, Germany
| | - Ria Baumgrass
- Signal Transduction, German Rheumatism Research Center, 10117 Berlin, Germany
| | - Stefan Wallner
- Institute of Clinical and Laboratory Medicine, University Hospital Regensburg, 93042 Regensburg, Germany
| | - Cristina Cadenas
- Leibniz Research Center for Working Environment and Human Factors, 44139 Dortmund, Germany
| | - Kathrin Gianmoena
- Leibniz Research Center for Working Environment and Human Factors, 44139 Dortmund, Germany
| | - Stefan Floess
- Experimental Immunology, Helmholz Center for Infection Research, 38124 Braunschweig, Germany
| | - Wei Chen
- Max Delbrück Center for Molecular Medicine, 13092 Berlin, Germany
| | - Karl Nordstroem
- Laboratory of Epigenetics, Saarland University, 66123 Saarbrücken, Germany
| | - Sascha Tierling
- Laboratory of Epigenetics, Saarland University, 66123 Saarbrücken, Germany
| | - Sven Olek
- Epiontis GmbH, 12489 Berlin, Germany; and
| | - Jörn Walter
- Laboratory of Epigenetics, Saarland University, 66123 Saarbrücken, Germany
| | - Alf Hamann
- Experimental Rheumatology, German Rheumatism Research Center, 10117 Berlin, Germany
| | - Uta Syrbe
- Medical Clinic for Gastroenterology, Infectious Diseases, and Rheumatology, Charité University Hospital, 12200 Berlin, Germany
| |
Collapse
|
4
|
Burrows GG, Van't Hof W, Reddy AP, Wilmarth PA, David LL, Raber A, Bogaerts A, Timmerman L, Pinxteren J, Roobrouck VD, Deans RJ, Maziarz RT. Solution-Phase Crosstalk and Regulatory Interactions Between Multipotent Adult Progenitor Cells and Peripheral Blood Mononuclear Cells. Stem Cells Transl Med 2015; 4:1436-49. [PMID: 26494783 PMCID: PMC4675500 DOI: 10.5966/sctm.2014-0225] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2014] [Accepted: 08/03/2015] [Indexed: 02/06/2023] Open
Abstract
UNLABELLED Multipotent adult progenitor cells (MAPCs) are adult adherent stromal stem cells currently being assessed in clinical trials for acute graft versus host disease with demonstrated immunomodulatory capabilities and the potential to ameliorate detrimental autoimmune and inflammation-related processes. Anti-CD3/anti-CD28 (3/28) activation of T cells within the peripheral blood mononuclear cell (PBMC) compartment was performed in the presence or absence of MAPCs. Liquid chromatography-coupled tandem mass spectrometry was used to characterize the differential secretion of proteins, and transcriptional profiling was used to monitor mRNA expression changes in both cell populations. Overall, 239 secreted and/or ectodomain-shed proteins were detected in the secretomes of PBMCs and MAPCs. In addition, 3/28 activation of PBMCs induced differential expression of 2,925 genes, and 22% of these transcripts were differentially expressed on exposure to MAPCs in Transwell. MAPCs exposed to 3/28-activated PBMCs showed differential expression of 1,247 MAPC genes. Crosstalk was demonstrated by reciprocal transcriptional regulation. Secretome proteins and transcriptional signatures were used to predict molecular activities by which MAPCs could dampen local and systemic inflammatory responses. These data support the hypothesis that MAPCs block PBMC proliferation via cell cycle arrest coupled to metabolic stress in the form of tryptophan depletion, resulting in GCN2 kinase activation, downstream signaling, and inhibition of cyclin D1 translation. These data also provide a plausible explanation for the immune privilege reported with administration of donor MAPCs. Although most components of the major histocompatibility complex class II antigen presentation pathway were markedly transcriptionally upregulated, cell surface expression of human leukocyte antigen-DR is minimal on MAPCs exposed to 3/28-activated PBMCs. SIGNIFICANCE This study documents experiments quantifying solution-phase crosstalk between multipotent adult progenitor cells (MAPCs) and peripheral blood mononuclear cells. The secretome and transcriptional changes quantified suggest mechanisms by which MAPCs are hypothesized to provide both local and systemic immunoregulation of inflammation. The potential impact of these studies includes development of a robust experimental framework to be used for preclinical evaluation of the specific mechanisms by which beneficial effects are obtained after treatment of patients with MAPCs.
Collapse
Affiliation(s)
- Gregory G Burrows
- Center for Hematologic Malignancies, Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon, USA
| | - Wouter Van't Hof
- Regenerative Medicine Program, Athersys Inc., Cleveland, Ohio, USA National Center for Regenerative Medicine, Cleveland, Ohio, USA
| | - Ashok P Reddy
- Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon, USA
| | - Phillip A Wilmarth
- Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon, USA
| | - Larry L David
- Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, Oregon, USA
| | - Amy Raber
- Regenerative Medicine Program, Athersys Inc., Cleveland, Ohio, USA
| | | | | | | | | | - Robert J Deans
- Regenerative Medicine Program, Athersys Inc., Cleveland, Ohio, USA National Center for Regenerative Medicine, Cleveland, Ohio, USA ReGenesys, Inc., Leuven, Belgium
| | - Richard T Maziarz
- Center for Hematologic Malignancies, Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA
| |
Collapse
|